Claims (13)
1. Spoj formule (1), ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju poremećaja središnjeg živčanog sustava
[image]
,
gdje se poremećaj središnjeg živčanog sustava bira iz skupine koju čine Friedreichova ataksija, ozljeda mozga, rijetka metabolička bolest, globalna ili lokalna ishemija, intracerebralno krvarenje, inzult, vaskularna demencija, meningitis uzrokovan virusnom infekcijom u živčanom sustavu, encefalitis uzrokovan virusnom infekcijom u živčanom sustavu, te metastaze primarnog tumora na mozgu.1. The compound of formula (1), or its pharmaceutically acceptable salt, characterized in that it is intended for use in the treatment or prevention of disorders of the central nervous system
[image]
,
wherein the central nervous system disorder is selected from the group consisting of Friedreich's ataxia, brain injury, rare metabolic disease, global or local ischemia, intracerebral hemorrhage, insult, vascular dementia, meningitis caused by a viral infection of the nervous system, encephalitis caused by a viral infection of the nervous system, and metastases of the primary brain tumor.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što ga se bira između spojeva (2) do (5):
(2) (R)-5-(4-(2-(5-((R)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
(3) (R)-5-(4-(2-(5-((S)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
(4) (S)-5-(4-(2-(5-((R)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona; i
(5) (S)-5-(4-(2-(5-((S)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
ili njihovih farmaceutski prihvatljivih soli.2. A compound intended for use in accordance with patent claim 1, characterized in that it is selected from compounds (2) to (5):
(2) (R)-5-(4-(2-(5-((R)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
(3) (R)-5-(4-(2-(5-((S)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
(4) (S)-5-(4-(2-(5-((R)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; and
(5) (S)-5-(4-(2-(5-((S)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
or pharmaceutically acceptable salts thereof.
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je najviše 0,015% od ukupnog broja atoma vodika po molu spoja u obliku izotopa 2H.3. A compound intended for use in accordance with patent claim 1 or patent claim 2, characterized in that no more than 0.015% of the total number of hydrogen atoms per mole of the compound is in the form of the 2H isotope.
4. Smjesa dva ili više spojeva, koju se bira između spojeva (2) do (5):
(2) (R)-5-(4-(2-(5-((R)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
(3) (R)-5-(4-(2-(5-((S)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
(4) (S)-5-(4-(2-(5-((R)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona; i
(5) (S)-5-(4-(2-(5-((S)-1-hidroksietil)piridin-2-il)etoksi)benzil)tiazolidin-2,4-diona;
ili njihovih farmaceutski prihvatljivih soli,
namijenjena upotrebi u liječenju ili sprječavanju poremećaja središnjeg živčanog sustava, naznačena time se što poremećaj bira iz skupine koju čine Friedreichova ataksija, ozljeda mozga, rijetka metabolička bolest, globalna ili lokalna ishemija, intracerebralno krvarenje, inzult, vaskularna demencija, meningitis uzrokovan virusnom infekcijom u živčanom sustavu, encefalitis uzrokovan virusnom infekcijom u živčanom sustavu, te metastaze primarnog tumora na mozgu.4. A mixture of two or more compounds, chosen from compounds (2) to (5):
(2) (R)-5-(4-(2-(5-((R)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
(3) (R)-5-(4-(2-(5-((S)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
(4) (S)-5-(4-(2-(5-((R)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; and
(5) (S)-5-(4-(2-(5-((S)-1-hydroxyethyl)pyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione;
or their pharmaceutically acceptable salts,
intended for use in the treatment or prevention of disorders of the central nervous system, indicated by the fact that the disorder is selected from the group consisting of Friedreich's ataxia, brain injury, rare metabolic disease, global or local ischemia, intracerebral hemorrhage, insult, vascular dementia, meningitis caused by a viral infection in the nervous system system, encephalitis caused by a viral infection in the nervous system, and metastases of a primary brain tumor.
5. Smjesa namijenjena upotrebi u skladu s patentnim zahtjevom 4, naznačena time što je se bira iz skupine koju čine:
(a) smjese koje sadrže spojeve (2) i (3);
(b) smjese koje sadrže spojeve (4) i (5);
(c) smjese koje sadrže spojeve (2) i (4); i
(d) smjese koje sadrže spojeve (3) i (5).5. The mixture intended for use in accordance with patent claim 4, characterized in that it is selected from the group consisting of:
(a) mixtures containing compounds (2) and (3);
(b) mixtures containing compounds (4) and (5);
(c) mixtures containing compounds (2) and (4); and
(d) mixtures containing compounds (3) and (5).
6. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeni time što je poremećaj Friedreichova ataksija.6. A compound, or mixture of compounds, intended for use in accordance with any of claims 1-5, characterized in that the disorder is Friedreich's ataxia.
7. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeni time što je poremećaj središnjeg živčanog sustava rijetka metabolička bolest.7. A compound, or a mixture of compounds, intended for use in accordance with any of claims 1-5, characterized in that the central nervous system disorder is a rare metabolic disease.
8. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što se također primjenjuje drugo terapijsko sredstvo.8. A compound, or a mixture of compounds, intended for use in accordance with any of claims 1-7, characterized in that another therapeutic agent is also applied.
9. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s patentnim zahtjevom 8, naznačeni time što se spoj ili smjesa spojeva i navedeno drugo terapijsko sredstvo osigurava u kombinaciji.9. Compound, or mixture of compounds, intended for use in accordance with patent claim 8, characterized in that the compound or mixture of compounds and said other therapeutic agent are provided in combination.
10. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačeni time što se spoj ili smjesa spojeva osigurava u farmaceutskom pripravku, poput oralnog oblika farmaceutskog pripravka.10. A compound, or mixture of compounds, intended for use in accordance with any of claims 1-9, characterized in that the compound or mixture of compounds is provided in a pharmaceutical preparation, such as an oral form of a pharmaceutical preparation.
11. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što je oralni oblik oralna otopina ili oralna suspenzija; ili što se oralni oblik bira iz skupine koju čine tablete, kapsule, pilule, te granule.11. A compound, or a mixture of compounds, intended for use in accordance with claim 10, characterized in that the oral form is an oral solution or oral suspension; or that the oral form is chosen from the group consisting of tablets, capsules, pills, and granules.
12. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 9-11, naznačeni time što su spoj ili smjesa spojeva u farmaceutskom pripravku u dozi od 0,1 mg do 200 mg ili od 10 mg do 100 mg.12. A compound, or a mixture of compounds, intended for use in accordance with any of patent claims 9-11, characterized in that the compound or mixture of compounds is in a pharmaceutical preparation in a dose of 0.1 mg to 200 mg or 10 mg to 100 mg .
13. Spoj, ili smjesa spojeva, namijenjeni upotrebi u skladu s patentnim zahtjevom 9, naznačeni time što je farmaceutski pripravak pogodan za topikalni, epikutani, supkutani, transdermalni, intramuslularni, parenteralni, okularni, rektalni, vaginalni, inhalacijski, bukalni, sublingvalni ili intranazalni unos, poput sublingvalnog oblika doziranja.13. A compound, or a mixture of compounds, intended for use in accordance with patent claim 9, characterized in that the pharmaceutical preparation is suitable for topical, epicutaneous, subcutaneous, transdermal, intramuscular, parenteral, ocular, rectal, vaginal, inhalation, buccal, sublingual or intranasal use intake, such as a sublingual dosage form.